Greenwich Lifesciences Inc expected to post a loss of 21 cents a share - Earnings Preview
11/04/2025 21:03
Greenwich Lifesciences Inc GLSI.OQ GLSI.O is expected to show no change in quarterly revenue when it reports results on April 14 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Greenwich Lifesciences Inc is for a loss of 21 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Greenwich Lifesciences Inc is $38.00, above its last closing price of $9.32. This summary was machine generated April 11 at 20:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio